pdf
Published
2022-07-28
Issue
Section
Pharmacy Practice & Practice-Based Research
Categories
License
Copyright (c) 2022 Abdulmajeed Alotaibi, Askal Ali, Clyde Brown, Fatimah Sherbeny
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright of content published in INNOVATIONS in pharmacy belongs to the author(s).
Exploratory Analysis of Survival and Mortality Rates among Older Lung Cancer Patients Utilizing Different Treatment Modalities
Abdulmajeed Alotaibi
Florida A&M University, School of Pharmacy
Askal Ali
Florida A&M University, School of Pharmacy
Clyde Brown
Florida A&M University, School of Public Health
Fatimah Sherbeny
Florida A&M University, School of Pharmacy
DOI: https://doi.org/10.24926/iip.v13i2.4346
Keywords: survival rate, lung cancer, treatment, mortality
Abstract
Objective: To explore the impact of different lung cancer treatment modalities on survival time and mortality rates in older patients.
Methods: The Surveillance Epidemiology and End Results (SEER) database was used to identify lung cancer patients aged ≥50 years old in the United States. Descriptive statistics and trend charts from 2000 to 2016 were generated. Regression analysis was performed among lung cancer patients to explore the association between survival time and treatment utilization (chemotherapy, radiation, and surgery). A regression model was also applied to explore the association between treatment modalities and odds of dying.
Results: A total of 826,217 patients were diagnosed with lung cancer between 2000-2016. The number of lung cancer cases increased by 7%, and the average annual frequency was 48,529 cases per year. Survival, mortality, and treatment utilization varied over the years based on demographic, clinical characteristics, and social status. Five-year survival rate was less than 10% among the study population, and 84% of included lung cancer patients died. Chemotherapy was more commonly used (62%), followed by radiation (35%) and surgical interventions (22%). Chemotherapy and surgery showed a survival advantage. The odds of dying were two times higher among patients treated with surgery than those who were not (OR: 2.62, 95%Cl: 2.58- 2.67).
Conclusion: This study highlighted the importance of considering treatment modalities and individual patient characteristics, which may impact survival times and mortality rates among older lung cancer patients.
